← All trials
NCT06763666
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2025
- Primary completion
- Jun 30, 2025
- Completion date
- Dec 31, 2025
- First posted
- Jan 8, 2025
- Last posted
- Jan 8, 2025
- Enrollment
- 172
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Southern Medical UniversityLead sponsor
- First People's Hospital of FoshanCollaborator
- Guangzhou Medical UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Southern Medical UniversityCollaborator
- Southern Medical UniversityCollaborator
- Southern Medical UniversityCollaborator
- Southern Medical UniversityOfficial
- Guangzhou Panyu Central HospitalCollaborator
- Central People's Hospital of ZhanjiangCollaborator
- Shantou UniversityCollaborator
- Yuebei People's HospitalCollaborator
- Guilin UniversityCollaborator
- Guangdong Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Huizhou People's Central HospitalCollaborator
- Jiangmen Central HospitalCollaborator
- Maoming People's HospitalCollaborator
- China Medical UniversityCollaborator
- Guangdong Second Provincial Traditional Chinese Medicine HospitalCollaborator
- Hacettepe UniversityCollaborator
- Xiamen UniversityCollaborator
- Peking UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Hainan People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.